2016 Canadian Cancer Statistics

full version (142 pages)

lifetime probability of developing ovarian cancer: 1 in 71
estimate new cases (2016):  2,800
estimated deaths(2016):      1,750

New York: Dear America, you’re already great. Love Canada: Social media campaign to boost U.S. spirits takes off

Blogger's Note: having a bad day? Read this:

Dear America, you’re already great. Love Canada: Social media campaign to boost U.S. spirits takes off 

 The campaign has spawned headlines on the websites of prominent news outlets based in the U.S., Britain and Canada.

NEW YORK — A social media campaign started by a Toronto-based creative agency has gained international attention for its effort to boost American spirits as the U.S. goes through a fractious presidential election.
Using the hashtag #tellamericaitsgreat, Canadians have swamped Twitter with compliments about American music, culture, technology and even tailgating. The outpouring of love triggered a reply — #TellCanadaThanks.
It’s all an effort started by the Toronto-based ad agency The Garden Collective, which chose its hashtag as a play on Republican presidential candidate Donald Trump’s campaign slogan, “Make America great again.” The firm’s video launching the social media push has gotten over 752,000 YouTube views and the hashtag has been trending on Twitter for several days. Many Canadians have made their own mini-videos, too.
Dic Dickerson, managing director of the firm, called it a pet project they devised for no other reason than to just spread love. “We put it out there and I don’t think any of us expected to get as much traction as it did but we’re really, really excited by all the positivity,” he said. “A lot of people are talking, which is exactly what we wanted.”....

When Clinical Care Depends on the Answer: The Challenges of Assessing Germline Cancer Gene Variants

Editorial - open access

 

Detection of Mismatch Repair Deficiency in Colorectal Cancers: Is It Really Time to Eliminate Immunohistochemistry?

Detection of Mismatch Repair Deficiency in Colorectal Cancers: Is It Really Time to Eliminate Immunohistochemistry?

Related Articles

• CORRESPONDENCE: Reply to G. Le Flahec et al
  

  • Joanne Ngeow and
  • Charis Eng

  JCO JCO699405; published online on October 17, 2016;
  • [Full Text]
  • [PDF]
• CORRESPONDENCE: Reply to G. Le Flahec et al
  

  • Zsofia K. Stadler and
  • Leonard B. Salt

  •  Thus, for patients undergoing either an IHC or NGS analysis of their tumors, decisions on charges, as opposed to costs, by either laboratories or payers may well dictate which manner of testing for MMR status is more cost effective. Duplication of effort, however, is always more costly, and for those patients whose tumors will as a matter of course undergo assessment via an NGS panel for RAS or BRAF or for other reasons, the additional performance of MMR IHC is likely to constitute an unnecessary expense that can and should be avoided.

  JCO JCO699413; published online on October 17, 2016;
  
  

  • [Full Text]
  • [PDF]

REFERENCES

1. 1.↵
   1. Stadler ZK,
   2. Battaglin F,
   3. Middha S,
   4. et al.

   (2016) Reliable detection of mismatch repair deficiency in colorectal cancers using mutational load in next-generation sequencing panels. J Clin Oncol 34:2141–2147.

   Abstract/FREE Full Text
2. 2.↵
   1. Le DT,
   2. Uram JN,
   3. Wang H,
   4. et al.

   (2015) PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med 372:2509–2520.

   CrossRefMedlineGoogle Scholar
3. 3.↵
   1. National Comprehensive Cancer Network

   , NCCN clinical practice guidelines in oncology (NCCN guidelines): Genetic/familial high-risk assessment—Colorectal. http://www.nccn.org/professionals/physician_gls/pdf/genetics_colon.pdf.
4. 4.↵
   1. Stoffel EM,
   2. Mangu PB,
   3. Limburg PJ

   (2015) Hereditary colorectal cancer syndromes: American Society of Clinical Oncology clinical practice guideline endorsement of the familial risk–colorectal cancer: European Society for Medical Oncology clinical practice guidelines. J Oncol Pract 11:e437–e441.

   FREE Full Text
5. 5.↵
   1. Uguen A,
   2. Guéguen P,
   3. Legoupil D,
   4. et al.

   (2015) Dual NRASQ61R and BRAFV600E mutation-specific immunohistochemistry completes molecular screening in melanoma samples in a routine practice. Hum Pathol 46:1582–1591.

   CrossRefMedlineGoogle Scholar
6. 6.↵
   1. Nolan S,
   2. Arnason T,
   3. Drucker A,
   4. et al.

   (2014) The utility of BRAFV600E mutation-specific antibody for colon cancers with microsatellite instability. Appl Immunohistochem Mol Morphol 22:e8–e13.

   CrossRefMedlineGoogle Scholar
7. 7.↵
   1. Turchini J,
   2. Andrici J,
   3. Sioson L,
   4. et al.

   NRASQ61R mutation-specific immunohistochemistry is highly specific for either NRASQ61R or KRASQ61R mutation in colorectal carcinoma. Appl Immunohistochem Mol Morphol, [epub ahead of print on February 9, 2016].

   Google Scholar
8. 8.↵
   1. Colling R,
   2. Wang LM,
   3. Soilleux E

   (2016) Automated PCR detection of BRAF mutations in colorectal adenocarcinoma: A diagnostic test accuracy study. J Clin Pathol 69:398–402.

   Abstract/FREE Full Text

open access: Perspectives of health care professionals on cancer cachexia: results from three global surveys

open access

Conclusions These surveys underscore the need for increased awareness among HCPs of CC and its management.

introduction

Cachexia is a debilitating condition with high occurrence in cancer patients, particularly in those with advanced disease [1, 2]; up to 20% of patients die as a result of cancer cachexia (CC) [3]. CC has been defined as a multifactorial syndrome characterized by muscle depletion, with or without loss of adipose tissue, which cannot be completely reversed by available treatments, leading to progressive functional derangements [4]. The pathophysiology of CC is characterized by reduced food intake and abnormal metabolism, which lead to a negative protein and energy balance [4]. The agreed-on diagnostic criteria for CC are a weight loss >5%, or a weight loss >2% in patients already showing depletion according to body mass index (BMI <20 kg/m²) or skeletal muscle mass [4].

......

surveys design and inclusion criteria

Three surveys were conducted among HCPs by Synovate Healthcare (now Ipsos Healthcare; Surveys 1 and 3) and Adelphi (Survey 2), between 2011 and 2012. The design of each study was developed according to the best market research practice. All questions were tested for understandability through an internal process among experts of the companies involved in the surveys' development. Since this was the first initiative in the field, the questions chosen for these surveys were not externally validated. Partial completion was not allowed or used for final analysis. Questions asked or discussed in the surveys and reported herein are described in supplementary Table S1, available at Annals of Oncology online.